PubRank

Scopolamine in Bipolar Depression (SCOPE-BD)

Clinical Trial ID NCT04211961

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04211961

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010 13.88
2 Identification of a family of muscarinic acetylcholine receptor genes. Science 1987 6.21
3 Bipolar disorder. N Engl J Med 2004 2.75
4 Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006 2.68
5 Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010 1.66
6 Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012 1.56
7 The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 1950 1.40
8 The STAR*D trial: revealing the need for better treatments. Psychiatr Serv 2009 1.33
9 mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade. Int J Neuropsychopharmacol 2011 1.28
10 Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2010 1.28
11 Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet 1961 1.26
12 Physostigmine in mania. Arch Gen Psychiatry 1978 1.07
13 M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res 2002 1.02
14 Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry 2013 1.02
15 The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 1988 0.97
16 Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006 0.97
17 The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry 1991 0.92
18 Cholinergic reversal of manic symptoms. Lancet 1972 0.91
19 Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res 2012 0.89
20 Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry 2010 0.87
21 Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord 2013 0.84
22 An empirical evaluation of the placebo run-in. Control Clin Trials 1995 0.82
23 Homeostatic regulation of sleep in a genetic model of depression in the mouse: effects of muscarinic and 5-HT1A receptor activation. Neuropsychopharmacology 2005 0.81
24 Antidepressant treatment history as a predictor of response to scopolamine: clinical implications. J Affect Disord 2014 0.79
25 Differential effects of scopolamine on nocturnal cortisol secretion, sleep architecture, and REM latency in normal volunteers: relation to sleep and cortisol abnormalities in depression. Biol Psychiatry 1989 0.78
26 Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients. Curr Psychiatry Rep 2011 0.78
27 The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord 2016 0.75
Next 100